AI Portfolio Summary
In 2025 Q4, Decheng Capital LLC maintained a portfolio of 23 distinct positions. They heavily accumulated shares in Lyell Immunopharma, , increasing their position by 16.2%. Conversely, Decheng Capital LLC completely exited their position in MERUS NV.
Total Positions
23
Quarter
2025 Q4
Top Holding
CGON (35.6%)
Top 10 Concentration
97.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-23 of 23
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
CGON
CG ONCOLOGY INC
|
Healthcare | 35.59% | 44.78% |
#1
Prev: #1
|
10.0 | no change | no change |
P
S
|
6,371,669 | $264,551,697 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVB
Nuvation Bio In...
|
Healthcare | 31.28% | 16.75% |
#2
Prev: #2
|
10.0 | no change | no change |
P
S
|
25,954,439 | $232,551,773 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UPB
Upstream Bio In...
|
Healthcare | 11.48% | 10.78% |
#3
Prev: #3
|
4.6 | -142,215 | -4.3% |
P
S
|
3,143,078 | $85,334,568 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AARD
AARDVARK THERAP...
|
Healthcare | 6.92% | 9.08% |
#4
Prev: #4
|
2.8 | no change | no change |
P
S
|
3,917,299 | $51,414,550 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LYEL
Lyell Immunopha...
|
Healthcare | 2.87% | 1.69% |
#5
3
Prev: #8
|
3.2 | 96,584 | 16.2% |
P
S
|
692,050 | $21,301,299 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NAMS
NEWAMSTERDAM PH...
|
Healthcare | 2.79% | 3.26% |
#6
1
Prev: #5
|
1.1 | -64,994 | -9.9% |
P
S
|
592,057 | $20,769,360 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 2.14% | 1.71% |
#7
Prev: #7
|
0.9 | -10,000 | -4.8% |
P
S
|
200,000 | $15,930,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RCUS
Arcus Bioscienc...
|
Healthcare | 1.74% | 1.30% |
#8
3
Prev: #11
|
0.7 | -6,050 | -1.1% |
P
S
|
541,559 | $12,905,351 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACRS
Aclaris Therape...
|
Healthcare | 1.64% | 1.34% |
#9
1
Prev: #10
|
0.7 | no change | no change |
P
S
|
4,041,736 | $12,165,625 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EQ
Equillium Inc.
|
Healthcare | 0.93% | 1.11% |
#10
2
Prev: #12
|
0.4 | no change | no change |
P
S
|
4,447,308 | $6,893,328 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BYSI
BeyondSpring In...
|
Healthcare | 0.83% | 1.35% |
#11
2
Prev: #9
|
0.4 | -485,402 | -11.3% |
P
S
|
3,800,702 | $6,195,145 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRNX
CRINETICS PHARM...
|
Healthcare | 0.58% | 1.04% |
#12
1
Prev: #13
|
0.3 | -50,300 | -35.2% |
P
S
|
92,700 | $4,315,185 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRYS
KRYSTAL BIOTECH...
|
Healthcare | 0.57% | 0.99% |
#13
1
Prev: #14
|
0.4 | -15,000 | -46.4% |
P
S
|
17,300 | $4,265,142 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AURA
Aura Bioscience...
|
Healthcare | 0.26% | 0.56% |
#14
1
Prev: #15
|
0.2 | -155,072 | -30.1% |
P
S
|
360,483 | $1,964,632 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ZNTL
Zentalis Pharma...
|
Healthcare | 0.24% | 0.35% |
#15
1
Prev: #16
|
0.1 | no change | no change |
P
S
|
1,323,327 | $1,786,491 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PYXS
Pyxis Oncology,...
|
Healthcare | 0.05% | 0.13% |
#16
4
Prev: #20
|
0.0 | no change | no change |
P
S
|
326,810 | $375,832 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FDMT
4D MOLECULAR TH...
|
Healthcare | 0.04% | 0.14% |
#17
1
Prev: #18
|
0.2 | -48,437 | -52.2% |
P
S
|
44,311 | $332,333 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVB/WS
Nuvation Bio In...
|
Bond/Debt | 0.03% | 0.02% |
#18
5
Prev: #23
|
0.0 | no change | no change |
P
S
|
646,057 | $213,198 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RZLT
REZOLUTE INC
|
Healthcare | 0.02% | 0.10% |
#19
3
Prev: #22
|
0.0 | no change | no change |
P
S
|
59,900 | $141,364 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS NV
|
Healthcare | 0.00% | 3.06% |
Sold All 😨
(Was: #6) |
0.3 | -186,546 | -100.0% |
CLOSED
|
— | $— | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
MOONLAKE IMMUNO...
|
—
|
Unknown | 0.00% | 0.23% |
Sold All 😨
(Was: #17) |
0.3 | -181,600 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
ILMN
Illumnia, Inc.
|
Healthcare | 0.00% | 0.13% |
Sold All 😨
(Was: #19) |
0.3 | -7,979 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GRAL
GRAIL INC
|
Healthcare | 0.00% | 0.10% |
Sold All 😨
(Was: #21) |
0.3 | -9,684 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-23 of 23 holdings